SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III
Sponsor: Cancer and Leukemia Group B
Listed as NCT00002651, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by Cancer and Leukemia Group B, it has been updated 9 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Feb 2017 — Jun 2017 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
May 1995
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Halifax, Canada , Kingston, Canada , London, Canada , Montreal, Canada , Ottawa, Canada , Québec, Canada , Saskatoon, Canada , Sherbrooke, Canada and 2 more locations